Biotechnology

As biotech and pharma risks evolve, Verist Inc. launches tailored coverage, aiming to redefine insurance with a high-touch, data-driven service model.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

NorthStar Medical Radioisotopes will showcase its revolutionary cancer-fighting isotopes, Ac-225 and Cu-67, at the prestigious J.P. Morgan conference.

CERo Therapeutics reports early safety success and dose escalation in its Phase 1 AML trial for CER-1236, a novel cell therapy for high-risk patients.

New data reveals a novel therapy shrinks tumors in salivary gland cancer, offering hope where few options exist and validating a new oncology platform.

Armed with breakthrough data on an AI-designed therapy that penetrates the brain, Rakovina Therapeutics heads to JPM Week to court major partners.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

New data shows Vyriad's VV169 eliminated myeloma in mice without severe toxicity, signaling a potential shift to safer, scalable 'off-the-shelf' CAR T.

A new AI platform promises human-like chats for doctors, aiming to solve pharma's compliance and information overload challenges with on-demand science.

Zephyrus Innovations just got FDA clearance for VaporShield, a device protecting nurses from drug exposure. It’s a story of safety, market disruption, and efficiency.

Ayrmid and RoslinCT forge a key manufacturing pact for a new SAA therapy, revealing the critical infrastructure needed for resilient biotech returns.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

One firm is ditching market predictions for a new approach: debunking costly myths. Here’s why this matters for healthcare leaders and investors.

When a superstorm threatened a 10,000-person conference, one firm's crisis response offered a masterclass in resilience with lessons for the entire industry.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?